Monitor PALISADE-4 topline results in Q2 2026 as the key binary catalyst. The ICH E1 milestone is a necessary but not sufficient step toward an NDA — FDA alignment on safety database requirements remains unresolved. The stock's $21M market cap implies binary risk around the Phase 3 readout.
Price Chart
Executive Summary
Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, with over 1,500 subjects receiving at least one dose, over 300 with at least 6 months of exposure, and over 100 with at least 12 months. This is a regulatory milestone for the NDA pathway, but the company has not yet aligned with the FDA on specific requirements. Topline results from the pivotal PALISADE-4 Phase 3 trial are expected in Q2 2026, and from the Phase 2 repeat dose study in Q3 2026.
Key Facts
- Fasedienol program exceeded ICH E1 minimum safety exposure recommendations as of May 31, 2026
- Over 1,500 subjects received at least a single exposure to fasedienol
- Over 300 subjects with at least 6 months of exposure
- Over 100 subjects with at least 12 months of exposure
- Vistagen has not yet aligned with the FDA on specific patient exposure requirements for an NDA
- Topline results from PALISADE-4 Phase 3 trial expected in Q2 2026
- Topline results from Phase 2 Repeat Dose study expected in Q3 2026
- Fasedienol has FDA Fast Track designation for acute treatment of social anxiety disorder
Financial Impact
No financial figures disclosed; milestone is regulatory/clinical, not financial
Risk Factors
- FDA has not yet agreed that the safety database is sufficient for NDA submission
- PALISADE-4 may fail to replicate PALISADE-2 positive results
- Company may need additional financing to complete development and regulatory submission
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-041962 |
| Document: vtgnex99106092026.htm | 0001628280-26-041962 |
| Document: 0001628280-26-041962-index-headers.html | 0001628280-26-041962 |
| Document: 0001628280-26-041962-index.html | 0001628280-26-041962 |
| Document: 0001628280-26-041962.txt | 0001628280-26-041962 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2847 (−6.39%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2847 (+6.39%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2847 (+18.13%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2847 (−25.97%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2847 (−57.52%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2847 (−58.74%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2847 (−50.32%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2847 (−46.79%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2847 (−55.52%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2847 (−54.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access